# Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

> **NCT04788745** · PHASE2 · COMPLETED · sponsor: **The University of Queensland** · enrollment: 21 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease

## Interventions

- **DRUG:** Trimetazidine Dihydrochloride

## Key facts

- **NCT ID:** NCT04788745
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-29
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-05-24
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-07-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04788745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04788745, "Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04788745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*